IN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio (Nasdaq: INAB) announced that CEO and co-founder William Ho will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:50 am ET in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IN8bio (Nasdaq: INAB) announced that CEO and co-founder William Ho will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:50 am ET in Boston. The company will host one-on-one investor meetings March 2-4.
A live webcast and replay will be available via the company’s Events and Presentations page at https://investors.in8bio.com.
Details
News Market Reaction – INAB
On Feb 24, the day this news came out, INAB closed 2.65% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Conference date
- March 2, 2026
- IN8bio presentation at TD Cowen 46th Annual Health Care Conference
- Presentation time
- 9:50 am ET
- Scheduled time for IN8bio company presentation
- Conference duration
- March 2–4, 2026
- TD Cowen 46th Annual Health Care Conference dates
Key Terms
gamma-delta (γδ) t cell therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET.
William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by members of management.
A live webcast and replay link for the TD Cowen conference can be found here, and will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.